Pharsight

Drugs that contain Crisaborole

1. Eucrisa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8039451 ANACOR PHARMS INC Boron-containing small molecules
Jun, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9682092 ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Feb, 2027

(2 years from now)

US8501712 ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Feb, 2027

(2 years from now)

US8501712

(Pediatric)

ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Aug, 2027

(3 years from now)

US9682092

(Pediatric)

ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Aug, 2027

(3 years from now)

US8039451

(Pediatric)

ANACOR PHARMS INC Boron-containing small molecules
Dec, 2029

(5 years from now)

US8168614 ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Jan, 2030

(5 years from now)

US8168614

(Pediatric)

ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Jul, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule (D) Apr 3, 2026

Market Authorisation Date: 14 December, 2016

Treatment: Method of treating mild to moderate atopic dermatitis.

Dosage: OINTMENT;TOPICAL

How can I launch a generic of EUCRISA before it's drug patent expiration?
More Information on Dosage

EUCRISA family patents

Family Patents